Cytokine Release Syndrome: A Hyperinflammatory Condition Triggered by Immune Therapies

Strategic Insights -

A recent study published in the journal Current Oncology has shed light on the pathogenesis, diagnosis, and management of Cytokine Release Syndrome (CRS), a hyperinflammatory state triggered by immune therapies like CAR T-cell therapy and bispecific T-cell engagers (BiTEs). According to the research, CRS often mimics infectious and inflammatory conditions, complicating diagnosis and treatment. The study highlights the importance of early recognition, differentiation from infectious mimics, and collaboration between oncology and infectious disease specialists to optimize CRS management and patient outcomes.

Key Takeaways:

  • CRS is a hyperinflammatory state triggered by immune therapies like CAR T-cell therapy and bispecific T-cell engagers (BiTEs), characterized by excessive cytokine release.
  • Immunoppressive therapies used for CRS further elevate the risk of secondary infections, affecting up to 23% of patients post-CAR T therapy and 24% post-BiTE therapy.
  • Pathogens associated with CRS include gram-positive and gram-negative bacteria, herpesviruses (e.g., CMV, HSV), fungi (e.g., *Candida*, *Aspergillus*), and parasites (e.g., Toxoplasma gondii).
  • Differentiation between CRS and non-infectious inflammatory syndromes remains challenging, but cytokine profiling and biomarkers (e.g., ferritin, CRP, sIL-2Ra) may aid in diagnosis.
  • Effective CRS management requires a multidisciplinary approach, including dedicated infectious disease input and pre-treatment evaluation.
  • Treatments for CRS include tocilizumab, corticosteroids, and empiric antimicrobials, with prophylactic strategies reported inconsistently.

Statistics:

  • Up to 23% of patients experienced infections post-CAR T cell therapy.
  • Up to 24% of patients experienced infections post-bispecific T-cell engagers (BiTEs) therapy.
  • The study reviewed 19,634 studies, with 2572 abstracts reviewed for inclusion.
  • 2572 abstracts were reviewed for the study, with 19,063 studies excluded.

Sources:

  • Pathogenesis, Diagnosis, and Management of Cytokine Release Syndrome in Patients with Cancer: Focus on Infectious Disease Considerations. Current Oncology, 2025,32(4):198. (MDPI AG)
  • Our news editors report that additional information may be obtained by contacting Panos Arvanitis, Division of Infectious Diseases, Brown University School of Medicine, Providence, RI 02903, United States.
  • Andreas Tziotis, Spyridon Papadimatos, Dimitrios Farmakiotis, Brown University Warren Alpert Medical School.